IMU Biosciences raised an expanded £53M Series A round to scale high-definition immune profiling technology and advance clinical programs. The company said the funding supports operational expansion, platform evolution, and clinical work including transplant rejection and immuno-oncology. The financing adds £28.5M to the initial close from January 2024, bringing total raised since formation in 2021 to £45M, and positions IMU to increase dataset generation and clinical translation. For the immune profiling market, the move underscores continued investor appetite for platforms that can turn immunology into scalable, high-dimensional measurements—often used for stratifying patients and assessing response mechanisms. If IMU’s large immune dataset can be translated effectively into clinical decision-making, it could strengthen biomarker development and speed up immunotherapy development cycles.